Pesticides & Agrochemicals · Founded 2000 · www.sumichem.co.in · BSE 542920 · NSE SUMICHEM · ISIN INE258G01013
No Notes Added Yet
Business
Sumitomo Chemical India Ltd. (SCIL) is a subsidiary of Sumitomo Chemical Co. Ltd., Japan, one of the world's leading chemical companies. SCIL is primarily engaged in the manufacturing, formulation, import, and marketing of a wide range of crop protection products (insecticides, herbicides, fungicides), plant growth regulators, and environmental health products in India. Its core business model revolves around leveraging its parent company's global R&D and product pipeline, adapting them for the Indian market, and distributing them through an extensive pan-India network to farmers and institutional buyers. The company makes money through the sale of these agricultural and public health solutions.
Revenue Mix
SCIL primarily operates in two main segments:
Crop Protection: This is the dominant segment, encompassing insecticides, herbicides, fungicides, and plant growth regulators. These products help farmers protect their crops from pests, diseases, and weeds, and enhance yield.
Environmental Health: This segment includes products for public health (e.g., mosquito control) and professional pest control.
While specific revenue contributions can vary, Crop Protection consistently accounts for the vast majority of the company's revenue.
Industry
SCIL operates in the Indian Pesticides & Agrochemicals industry, which is a crucial sector for food security and agricultural productivity. The industry is characterized by a mix of domestic and multinational players. SCIL benefits significantly from its global parentage, giving it access to advanced chemistry, a robust R&D pipeline, and technical expertise. It competes with other large Indian agrochemical companies (e.g., UPL, PI Industries, Rallis India) and subsidiaries of other global giants (e.g., Bayer, Syngenta). SCIL is positioned as a provider of quality, innovative, and differentiated products, leveraging its parent's patented molecules and strong brand recognition.
MOAT
Global Parentage & R&D: Access to Sumitomo Chemical, Japan's extensive global R&D capabilities, patented molecules, and technical know-how provides a significant competitive edge in developing and introducing advanced crop protection solutions.
Strong Brand & Product Portfolio: The Sumitomo name carries a reputation for quality and efficacy in the agricultural community, fostering trust among farmers. The company offers a diverse portfolio of products tailored to various crops and pest issues.
Extensive Distribution Network: SCIL has a well-established and wide distribution network across India, ensuring broad market reach even in remote agricultural areas.
Formulation Expertise: Ability to localize global products and develop formulations suitable for Indian climatic conditions and farming practices.
Growth Drivers
Increasing Food Demand: India's growing population and the global demand for food drive the need for higher agricultural productivity, increasing the usage of crop protection chemicals.
New Product Introductions: Continuous launch of new and differentiated products from its parent's global pipeline, often with better efficacy and margins.
Shift Towards Specialty Chemicals: Focus on high-value, specialty, and patented molecules, which command better pricing and margins compared to generic products.
Agricultural Reforms & Modernization: Government initiatives and farmer education promoting better farming practices and input usage.
Export Opportunities: Potential to expand exports to other developing markets, leveraging India's cost-effective manufacturing base.
Risks
Monsoon Dependence: Indian agriculture is heavily reliant on monsoon patterns. Unfavorable or erratic monsoons can significantly impact agricultural output and, consequently, demand for agrochemicals.
Regulatory Changes: Stringent environmental regulations, changes in product registration processes, or bans on certain molecules by Indian authorities can impact sales and product pipelines.
Competition & Pricing Pressure: The Indian agrochemical market is competitive, with numerous domestic and international players, leading to potential pricing pressures, especially in generic segments.
Raw Material Price Volatility: Fluctuations in crude oil prices and other chemical intermediates can impact manufacturing costs and profitability.
Counterfeit Products: The presence of counterfeit or sub-standard products in the market poses a risk to brand reputation and legitimate sales.
Pest Resistance: Continuous use of certain chemicals can lead to pest resistance, necessitating ongoing R&D and product innovation.
Management & Ownership
Sumitomo Chemical India Ltd. is a professionally managed company with its promoter, Sumitomo Chemical Co. Ltd., Japan, holding a significant majority stake (approximately 75%). This strong promoter holding ensures strategic alignment with the global parent's vision and benefits from its extensive expertise and corporate governance standards. The management team comprises experienced professionals from the chemical and agricultural sectors, drawing upon the parent company's global best practices.
Outlook
Sumitomo Chemical India Ltd. is well-positioned in the Indian agrochemical market, benefiting from its global parent's R&D prowess, strong product portfolio, and extensive distribution network. The company is likely to see steady growth driven by increasing agricultural demand and new product introductions, particularly in specialty chemicals, which promise better margins. However, its performance remains susceptible to the vagaries of the monsoon, intense competition, and evolving regulatory landscape in India. While its global backing provides a significant buffer and access to advanced solutions, the company must continuously innovate and manage operational risks to sustain its growth trajectory and profitability in the dynamic Indian agricultural sector.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 903 | 542 | 674 | 839 | 988 | 642 | 679 | 1057 | 930 | 568 |
| Other Income | 25 | 27 | 27 | 26 | 31 | 31 | 32 | 39 | 39 | 37 |
| Total Income | 928 | 569 | 701 | 865 | 1020 | 673 | 711 | 1096 | 969 | 605 |
| Total Expenditure | 716 | 476 | 534 | 678 | 743 | 536 | 560 | 838 | 712 | 468 |
| Operating Profit | 213 | 93 | 167 | 187 | 277 | 137 | 151 | 258 | 257 | 136 |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 16 | 16 | 17 | 15 | 16 | 19 | 16 | 16 | 17 | 17 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16 |
| Profit Before Tax | 195 | 75 | 149 | 171 | 260 | 117 | 133 | 241 | 238 | 102 |
| Provision for Tax | 52 | 21 | 39 | 44 | 67 | 29 | 33 | 62 | 60 | 26 |
| Profit After Tax | 143 | 55 | 110 | 127 | 193 | 87 | 100 | 178 | 178 | 76 |
| Adjustments | 0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | -0 |
| Profit After Adjustments | 143 | 55 | 110 | 127 | 192 | 87 | 100 | 178 | 178 | 76 |
| Adjusted Earnings Per Share | 2.9 | 1.1 | 2.2 | 2.5 | 3.9 | 1.7 | 2 | 3.6 | 3.6 | 1.5 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1913 | 2228 | 2425 | 2645 | 3061 | 3511 | 2844 | 3149 | 3234 |
| Other Income | 30 | 8 | 11 | 19 | 27 | 51 | 96 | 120 | 147 |
| Total Income | 1943 | 2236 | 2435 | 2663 | 3088 | 3562 | 2940 | 3269 | 3381 |
| Total Expenditure | 1693 | 1938 | 2090 | 2157 | 2459 | 2850 | 2369 | 2516 | 2578 |
| Operating Profit | 250 | 298 | 345 | 507 | 629 | 712 | 571 | 753 | 802 |
| Interest | 5 | 4 | 7 | 7 | 8 | 6 | 6 | 7 | 8 |
| Depreciation | 24 | 28 | 41 | 47 | 45 | 52 | 62 | 66 | 66 |
| Exceptional Income / Expenses | 0 | -7 | -31 | 0 | 0 | 0 | 0 | 0 | -16 |
| Profit Before Tax | 221 | 260 | 267 | 453 | 576 | 654 | 503 | 680 | 714 |
| Provision for Tax | 76 | 94 | 62 | 108 | 152 | 152 | 133 | 174 | 181 |
| Profit After Tax | 145 | 166 | 205 | 345 | 424 | 502 | 370 | 506 | 532 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -1 | 0 |
| Profit After Adjustments | 145 | 166 | 205 | 345 | 424 | 502 | 370 | 505 | 532 |
| Adjusted Earnings Per Share | 5.3 | 6 | 4.1 | 6.9 | 8.5 | 10.1 | 7.4 | 10.1 | 10.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 11% | 1% | 5% | 0% |
| Operating Profit CAGR | 32% | 6% | 17% | 0% |
| PAT CAGR | 37% | 6% | 20% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -9% | 7% | 9% | NA% |
| ROE Average | 19% | 19% | 21% | 21% |
| ROCE Average | 26% | 26% | 29% | 27% |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 954 | 1048 | 1222 | 1541 | 1927 | 2382 | 2442 | 2901 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 33 | 30 | 43 | 50 | 61 | 54 | 67 | 93 |
| Total Current Liabilities | 672 | 781 | 840 | 1081 | 1021 | 933 | 801 | 965 |
| Total Liabilities | 1658 | 1860 | 2105 | 2672 | 3010 | 3369 | 3313 | 3963 |
| Fixed Assets | 267 | 279 | 319 | 309 | 390 | 430 | 563 | 556 |
| Other Non-Current Assets | 46 | 39 | 40 | 58 | 97 | 151 | 77 | 387 |
| Total Current Assets | 1346 | 1542 | 1746 | 2304 | 2522 | 2788 | 2673 | 3020 |
| Total Assets | 1658 | 1860 | 2105 | 2672 | 3010 | 3369 | 3313 | 3963 |
| #(Fig in Cr.) | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 59 | 74 | 50 | 93 | 188 | 57 | 47 | 47 |
| Cash Flow from Operating Activities | 47 | 78 | 221 | 425 | 222 | 389 | 757 | 453 |
| Cash Flow from Investing Activities | -40 | -35 | -118 | -283 | -290 | -327 | -420 | -392 |
| Cash Flow from Financing Activities | 7 | -65 | -61 | -47 | -63 | -73 | -337 | -69 |
| Net Cash Inflow / Outflow | 15 | -23 | 42 | 96 | -131 | -10 | -0 | -8 |
| Closing Cash & Cash Equivalent | 74 | 50 | 93 | 188 | 57 | 47 | 47 | 38 |
| # | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 5.28 | 6.04 | 4.1 | 6.92 | 8.49 | 10.06 | 7.4 | 10.13 |
| CEPS(Rs) | 6.15 | 7.05 | 4.92 | 7.85 | 9.38 | 11.1 | 8.65 | 11.47 |
| DPS(Rs) | 0 | 2.29 | 0.55 | 0.8 | 1 | 1.2 | 5.9 | 1.2 |
| Book NAV/Share(Rs) | 26.57 | 30 | 24.48 | 30.88 | 38.61 | 47.72 | 48.91 | 58.12 |
| Core EBITDA Margin(%) | 11.19 | 11.6 | 12.25 | 16.09 | 17.08 | 16.68 | 14.73 | 18.13 |
| EBIT Margin(%) | 11.54 | 10.51 | 10.01 | 15.17 | 16.56 | 16.66 | 15.77 | 19.68 |
| Pre Tax Margin(%) | 11.26 | 10.36 | 9.76 | 14.94 | 16.34 | 16.51 | 15.6 | 19.49 |
| PAT Margin (%) | 7.4 | 6.61 | 7.49 | 11.39 | 12.02 | 12.67 | 11.47 | 14.51 |
| Cash Profit Margin (%) | 8.61 | 7.72 | 8.99 | 12.92 | 13.29 | 13.98 | 13.39 | 16.41 |
| ROA(%) | 8.75 | 9.42 | 10.32 | 14.46 | 14.91 | 15.75 | 11.07 | 13.92 |
| ROE(%) | 19.89 | 21.35 | 20.01 | 25 | 24.42 | 23.31 | 15.33 | 18.96 |
| ROCE(%) | 23.48 | 25.94 | 23.9 | 33.31 | 33.66 | 30.65 | 21.09 | 25.71 |
| Receivable days | 102.66 | 89 | 101.59 | 102.15 | 87.59 | 82.4 | 94.05 | 78.42 |
| Inventory Days | 113.36 | 93.88 | 84.74 | 80.75 | 87.63 | 84.12 | 84.84 | 68.73 |
| Payable days | 175.76 | 142.73 | 120.74 | 132.94 | 117.2 | 88.86 | 102.65 | 100.02 |
| PER(x) | 0 | 0 | 44.73 | 42.04 | 52.98 | 42.27 | 46.92 | 55.17 |
| Price/Book(x) | 0 | 0 | 7.49 | 9.42 | 11.64 | 8.91 | 7.1 | 9.61 |
| Dividend Yield(%) | 0 | 0 | 0.3 | 0.28 | 0.22 | 0.28 | 1.7 | 0.21 |
| EV/Net Sales(x) | 0.11 | 0.11 | 3.74 | 5.4 | 7.3 | 5.96 | 6.03 | 8.84 |
| EV/Core EBITDA(x) | 0.84 | 0.81 | 26.24 | 28.16 | 35.58 | 29.38 | 30.06 | 36.99 |
| Net Sales Growth(%) | 0 | 16.5 | 8.81 | 9.08 | 15.74 | 14.69 | -19 | 10.71 |
| EBIT Growth(%) | 0 | 16.44 | 3.81 | 68.21 | 26.83 | 13.14 | -22.98 | 35.03 |
| PAT Growth(%) | 0 | 14.25 | 23.46 | 68.74 | 22.62 | 18.57 | -26.38 | 36.97 |
| EPS Growth(%) | 0 | 14.25 | -32.08 | 68.69 | 22.66 | 18.57 | -26.42 | 36.79 |
| Debt/Equity(x) | 0.01 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio(x) | 2 | 1.97 | 2.08 | 2.13 | 2.47 | 2.99 | 3.34 | 3.13 |
| Quick Ratio(x) | 1.1 | 1.1 | 1.38 | 1.43 | 1.55 | 2.04 | 2.58 | 2.4 |
| Interest Cover(x) | 42.11 | 70.93 | 38.61 | 66.45 | 73.17 | 106.41 | 89.35 | 104.18 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| FII | 2.61 | 2.75 | 3.07 | 3.49 | 3.59 | 3.63 | 3.65 | 3.65 | 3.37 | 3.4 |
| DII | 6.02 | 6.64 | 7.14 | 6.97 | 6.96 | 8.14 | 8.15 | 8.47 | 8.65 | 8.98 |
| Public | 16.36 | 15.62 | 14.8 | 14.54 | 14.45 | 13.23 | 13.2 | 12.88 | 12.97 | 12.61 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 |
| FII | 1.31 | 1.37 | 1.53 | 1.74 | 1.79 | 1.81 | 1.82 | 1.82 | 1.68 | 1.7 |
| DII | 3.01 | 3.31 | 3.56 | 3.48 | 3.47 | 4.06 | 4.07 | 4.23 | 4.32 | 4.48 |
| Public | 8.17 | 7.79 | 7.39 | 7.26 | 7.21 | 6.61 | 6.59 | 6.43 | 6.48 | 6.3 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +11% | +1% | +5% | — |
| Operating Profit CAGR | +32% | +6% | +17% | — |
| PAT CAGR | +37% | +6% | +20% | — |
| Share Price CAGR | -9% | +7% | +9% | — |
| ROE Average | +19% | +19% | +21% | +21% |
| ROCE Average | +26% | +26% | +29% | +27% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 | 75 |
| FII | 2.61 | 2.75 | 3.07 | 3.49 | 3.59 | 3.63 | 3.65 | 3.65 | 3.37 | 3.4 |
| DII | 6.02 | 6.64 | 7.14 | 6.97 | 6.96 | 8.14 | 8.15 | 8.47 | 8.65 | 8.98 |
| Public | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 | 37.44 |
| FII | 1.31 | 1.37 | 1.53 | 1.74 | 1.79 | 1.81 | 1.82 | 1.82 | 1.68 | 1.7 |
| DII | 3.01 | 3.31 | 3.56 | 3.48 | 3.47 | 4.06 | 4.07 | 4.23 | 4.32 | 4.48 |
| Public | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 | 12.48 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 | 49.91 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.